2012
DOI: 10.1159/000342487
|View full text |Cite
|
Sign up to set email alerts
|

Comorbid Heart Failure and Renal Impairment: Epidemiology and Management

Abstract: Heart failure mortality is significantly increased in patients with baseline renal impairment and those with underlying heart failure who subsequently develop renal dysfunction. This accelerated progression occurs independent of the cause or grade of renal dysfunction and baseline risk factors. Recent large prospective databases have highlighted the depth of the current problem, while longitudinal population studies support an increasing disease burden. We have extensively reviewed the epidemiological and ther… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
27
0
3

Year Published

2013
2013
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 21 publications
(30 citation statements)
references
References 252 publications
0
27
0
3
Order By: Relevance
“…12) Comorbid HF and renal impairment is an evolving epidemic faced by an increasing number of medical practitioners and HF mortality is significantly increased in patients with baseline renal impairment and those with underlying HF who subsequently develop renal dysfunction. 13,14) The aim of the present meta-analysis, therefore, was to evaluate the efficacy and safety of UF with decompensated heart failure patients complicated by renal insufficiency.…”
mentioning
confidence: 99%
“…12) Comorbid HF and renal impairment is an evolving epidemic faced by an increasing number of medical practitioners and HF mortality is significantly increased in patients with baseline renal impairment and those with underlying HF who subsequently develop renal dysfunction. 13,14) The aim of the present meta-analysis, therefore, was to evaluate the efficacy and safety of UF with decompensated heart failure patients complicated by renal insufficiency.…”
mentioning
confidence: 99%
“…(2013), а изменения МАУ также положительно коррелировали с изменения-ми концентрации NT-proBNP и являлись индикаторами диагностики тяжести заболевания и прогноза. Так, значе-ния МАУ более 300 мг / л (А3) увеличивают риск насту-пления комбинированной первичной конечной точки в 6 раз (ОР 95 % 5,946 [1,611]; р=0,026).…”
Section: Discussionunclassified
“…(2015), ОПП ассоциировалось с увеличени-ем относительного риска смерти в 1,81 раза (ОР 95 % 1,81 [1,12]; р<0,001) [29]. Частота ОПП в нашем исследовании составила 9,9 % и ассоциировалась не толь-ко с увеличением частоты наступления комбинированной первичной точки (р=0,007) и повторных госпитализации в связи с ОСН (р=0,005), но также частоты случаев насту-пления смерти (p<0,001), ОПП увеличивала риск повтор-ной госпитализации в связи с ОСН в 8 раз (ОР 95 % 8,377 [1,996]; р=0,007) и многократно повышала риск смерти (ОР 95 % 9,956 [3,652]; р<0,001).…”
Section: Discussionunclassified
See 1 more Smart Citation
“…• Renal failure the strongest predictor of mortality even greater than LVEF is common and has a bidirectional effect, with increasing morbidity and mortality with grade [16];…”
Section: Introductionmentioning
confidence: 99%